Literature DB >> 28685355

Predictive Factors of Lymph Node Metastasis in Follicular Variant of Papillary Thyroid Carcinoma.

Seo Ki Kim1, Ah-Young Kwon2, Kyorim Back1, Inhye Park1, Nayoon Hur1, Jun Ho Lee3, Jun-Ho Choe4, Jung-Han Kim1, Young Lyun Oh2, Jee Soo Kim5.   

Abstract

BACKGROUND: Compared with conventional papillary thyroid carcinoma (PTC), follicular variant of PTC (FV-PTC) shows less aggressive behavior and better prognosis. Nonetheless, regional lymph node (LN) metastasis was found in 22.8% of FV-PTC patients. Because LN metastasis is a proven predictor of recurrence in PTC, it is important to assess LN metastasis in FV-PTC patients.
METHODS: We retrospectively reviewed 134 FV-PTC patients who underwent thyroidectomy with neck dissection.
RESULTS: Central LN metastasis (CLNM) and lateral LN metastasis (LLNM) were found in 50 (37.3%) and 16 (11.9%) patients, respectively. In the multivariate analysis for CLNM, male sex (adjusted OR 4.735, p = 0.001), nonencapsulated form (adjusted OR 2.863, p = 0.022), and tumor size >1.0 cm (adjusted OR 3.157, p = 0.008) were independent predictors of high prevalence of CLNM in FV-PTC patients. In the multivariate analysis for LLNM, microscopic extrathyroidal extension (ETE) (adjusted OR 3.939, p = 0.041) and CLNM (adjusted OR 13.340, p = 0.001) were independent predictors of high prevalence of LLNM in FV-PTC patients.
CONCLUSIONS: Meticulous perioperative evaluation and prophylactic central neck dissection may be beneficial for FV-PTC patients with male sex, nonencapsulated form, and tumor size >1.0 cm. Moreover, cautious perioperative evaluation of lateral neck LN may be mandatory for FV-PTC patients with microscopic ETE and CLNM.

Entities:  

Mesh:

Year:  2017        PMID: 28685355     DOI: 10.1245/s10434-017-5912-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Underexpression of INPPL1 is associated with aggressive clinicopathologic characteristics in papillary thyroid carcinoma.

Authors:  Yi-Li Zhou; Chen Zheng; Yi-Tong Chen; Xue-Min Chen
Journal:  Onco Targets Ther       Date:  2018-11-01       Impact factor: 4.147

2.  Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.

Authors:  Chen Zheng; Rui-Da Quan; Cheng-Yong Wu; Jing Hu; Bang-Yi Lin; Xu-Bing Dong; Er-Jie Xia; Adheesh Bhandari; Xiao-Hua Zhang; Ou-Chen Wang
Journal:  J Cell Mol Med       Date:  2019-09-30       Impact factor: 5.310

3.  Downregulation of CDH16 in Papillary Thyroid Cancer and Its Potential Molecular Mechanism Analysed by qRT-PCR, TCGA and in silico Analysis.

Authors:  Pihong Li; Qiaolin Wu; Yihan Sun; Xiaoyu Pan; Yifan Han; Bing Ye; Yinlong Zhang; Jianda Dong; Zhouci Zheng
Journal:  Cancer Manag Res       Date:  2019-12-23       Impact factor: 3.989

4.  A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma.

Authors:  Zhou-Ci Zheng; Qing-Xuan Wang; Wei Zhang; Xiao-Hua Zhang; Du-Ping Huang
Journal:  Onco Targets Ther       Date:  2018-01-11       Impact factor: 4.147

5.  Expression of ANGPTL2 and its impact on papillary thyroid cancer.

Authors:  Longyan Yang; Rongxin Sun; Yan Wang; Ying Fu; Yuanyuan Zhang; Zhaohui Zheng; Zhili Ji; Dong Zhao
Journal:  Cancer Cell Int       Date:  2019-07-30       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.